More than 747,000 packages of eye drops and ophthalmic ointments are being removed from retail shelves across the United States due to unresolved sterility concerns. The nationwide corrective action involves multiple popular drugstore chains, with more than half a million units sold under the Walgreens private label alone.

The Food and Drug Administration confirmed the formal regulatory standing of the market withdrawal, which covers saline solutions, artificial tears, and lubricating formulas designed for dry eye irritation. Production of every affected batch originated at the Sterling Pharmaceutical Services LLC manufacturing plant located in Dupo, Illinois.

Regulatory scope and manufacturing details at the Illinois plant

• Responsible manufacturer: Sterling Pharmaceutical Services LLC
• Manufacturing location: Dupo, Illinois, United States
• Total volume removed: 747,844 units across bottles, twin packs, and ointment tubes
• Product diversity: 9 separate commercial formulations
• Regulatory status: Class II classification by the Food and Drug Administration

The regulatory scrutiny in Dupo does not mark the company’s first interaction with federal drug monitors. The Food and Drug Administration issued a formal warning letter to Sterling Pharmaceutical Services LLC in September 2022, detailing serious quality violations regarding inadequate sterile line controls and deficient environmental air sampling inside packaging cleanrooms.

Current enforcement concentrates on over-the-counter formulations that rely on standard ocular active ingredients, such as carboxymethylcellulose sodium at 0.5%, hypertonic sodium chloride solutions at 5%, and soothing petroleum-based night ointments. Because ocular surfaces lack the outer defense layers present on human skin, applying non-sterile medication directly onto the cornea creates immediate risks of harmful microbial infiltration.

Breakdown of affected brands and distribution volume

• Walgreens Lubricant Eye Drops in 15 mL individual bottles: 301,114 units
• Walgreens Lubricant Eye Drops in double-pack cartons: 199,600 packages
• AvKare Carboxymethylcellulose Sodium 0.5% in double-pack cartons: 107,377 packages
• Reliable-1 Laboratories Lubricating Tears in 15 mL bottles: 47,616 bottles
• Major LubriFresh P.M. nighttime ointment in 3.5-gram tubes: 34,368 tubes
• Cameron Pharmaceuticals Carboxymethylcellulose Sodium 0.5% in 15 mL bottles: 19,284 bottles
• TRP The Relief Products Gentle Eyes in 15 mL bottles: 14,538 bottles
• AvKare Carboxymethylcellulose Sodium 0.5% in 15 mL individual bottles: 12,864 packages
• Reliable-1 Laboratories hypertonic sodium chloride 5% in 15 mL bottles: 11,083 units

Federal regulators classified the ongoing withdrawal under the Class II designation. Under official Food and Drug Administration criteria, this classification covers incidents where the use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.

Follow: FDA classifies recall of six hand soaps across 15 states

Public health monitors stated that no verified reports of severe ocular infections, permanent corneal damage, or vision loss have been linked to these specific manufactured items so far. Company representatives from Sterling Pharmaceutical Services LLC were asked to clarify the root cause of the aseptic processing lapse, but they did not provide a comment prior to publication.

Instructions for patients holding affected bottles

The recall affects any consumer who purchased over-the-counter lubricating eye preparations or nighttime ointments from the impacted brands through retail outlets or online shipments. Agency guidelines advise patients to check the packaging, outer carton, and container base immediately to match the brand name, batch code, and expiration dates with the enforcement record released by federal regulators.

Read also: Volkswagen Group recalls four million vehicles over steering bolt defect

Individuals who possess units matching the designated lots must discontinue application immediately and dispose of the bottles in accordance with local medication disposal standards. Anyone who applied the recalled drops and experiences persistent ocular pain, abnormal discharge, eyelid swelling, redness, or sudden changes in visual acuity should consult an eye care specialist or emergency medical provider for a clinical examination.

Key timeline of the nationwide regulatory intervention

• August 20, 2026: Sterling Pharmaceutical Services LLC voluntarily started the withdrawal of the nine eye product lines.
• September 21, 2026: The Food and Drug Administration formally assigned the Class II classification to the nationwide action.
• October 2, 2026: Public dissemination of the enforcement report providing precise distribution counts and batch identifications.

Distribution networks and retail pharmacy teams continue tracing the 747,844 distributed units across logistical supply routes to guarantee that all remaining inventory is permanently removed from commercial inventory. Field inspectors and supply chain managers are tracking returns from regional distribution hubs to verify complete removal across all participating retail chains.